MARKET

NURO

NURO

NeuroMetrix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3225
-0.0079
-2.40%
Opening 14:27 10/14 EDT
OPEN
0.3350
PREV CLOSE
0.3304
HIGH
0.3399
LOW
0.3100
VOLUME
80.11K
TURNOVER
--
52 WEEK HIGH
1.380
52 WEEK LOW
0.2749
MARKET CAP
3.15M
P/E (TTM)
-0.6116
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of NURO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

NURO News

  • NeuroMetrix, Inc. Announces Date for Third Quarter 2019 Financial Results Conference Call
  • GlobeNewswire.4d ago
  • The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO
  • Benzinga.4d ago
  • The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo
  • Benzinga.10/03 11:34
  • 22 Healthcare Stocks Moving In Monday's Pre-Market Session
  • Benzinga.09/16 12:29

More

Industry

Medical Equipment, Supplies & Distribution
-0.03%
Healthcare Equipment & Supplies
-0.03%

Hot Stocks

Name
Price
%Change

About NURO

NeuroMetrix, Inc. is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. Its products include ADVANCE NCS/EMG System (the ADVANCE System), Quell, SENSUS and DPNCheck. Quell is a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems. The SENSUS pain therapy device, the technological predecessor to Quell, is a prescription neuro-stimulation device based on transcutaneous electrical nerve stimulation (TENS) for relief of chronic, intractable pain. DPNCheck is a quantitative nerve conduction test. ADVANCE System is a platform for the performance of traditional nerve conduction studies.
More

Webull offers Neurometrix Inc (NURO) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.